GlassScriptPhysician profile
Jason B Bergman
NPI 1326056722
$5,895.58
in general payments reported to CMS, 2019-2025
40 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $1,269 · 2021: $1,791 · 2022: $893 · 2023: $188 · 2024: $146 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604 · Consulting Fee: $18.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.73 |
| Consulting Fee | $18.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,041.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $832.99 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.98 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $521.55 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $424.61 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $247.52 | 2020-2022 | |
| Glaxosmithkline, LLC. | $246.93 | 2019-2021 | |
| Abbott Laboratories | $191.01 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $162.91 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $156.27 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $154.03 | 2019-2022 | |
| Pfizer INC. | $148.18 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $122.57 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $98.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $97.37 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bergman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.